

国家卫生健康委员会中国结直肠癌诊疗规范(2023 版)

参考文献

- [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660.
- [2] 朱云峰, 陈晓飞. 粪便隐血试验与 SDC2 基因甲基化检测在结直肠癌筛查中的效果评价[J].中国肿瘤,2022,31(9):723-727. DOI: 10.11735/j.issn.1004-0242.2022.09.A007.
- [3] 乐晨琴, 刘成成, 胡烨婷, 等. 美国一般风险人群结直肠癌筛查指南更新解读[J].中华胃肠外科杂志,2022,25(9):826-833. DOI: 10.3760/cma.j.cn441530-20220220-00055.
- [4] 中国抗癌协会家族遗传性肿瘤专业委员会. 中国家族遗传性肿瘤临床诊疗专家共识(2021 年版)(4)——家族遗传性结直肠癌[J].中国肿瘤临床,2022,49(1):1-5. DOI: 10.12354/j.issn.1000-8179.2022.20211802.
- [5] Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)[J]. Chin J Cancer Res, 2019,31(1):117-134. DOI: 10.21147/j.issn.1000-9604.2019.01.07.
- [6] Li J, Yuan Y, Yang F, et al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)[J]. J Hematol Oncol, 2019,12(1):16. DOI: 10.1186/s13045-019-0702-0.
- [7] Beets-Tan R, Lambregts D, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018,28(4):1465-1475. DOI: 10.1007/s00330-017-5026-2.
- [8] Rouleau Fournier F, Motamedi M, Brown CJ, et al. Oncologic outcomes associated with MRI-detected Extramural Venous Invasion (mrEMVI) in rectal cancer: a systematic review and meta-analysis[J]. Ann Surg, 2022,275(2):303-314. DOI: 10.1097/SLA.0000000000004636.
- [9] Hoendervangers S, Burbach J, Lacle MM, et al. Pathological complete response following different neoadjuvant treatment strategies for locally advanced rectal cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2020,27(11):4319-4336. DOI: 10.1245/s10434-020-08615-2.

- [10] Park SH, Cho SH, Choi SH, et al. MRI assessment of complete response to preoperative chemoradiation therapy for rectal cancer: 2020 guide for practice from the Korean society of abdominal radiology[J]. Korean J Radiol, 2020,21(7):812-828. DOI: 10.3348/kjr.2020.0483.
- [11] Muaddi H, Silva S, Choi WJ, et al. When is a ghost really gone? A systematic review and meta-analysis of the accuracy of imaging modalities to predict complete pathological response of colorectal cancer liver metastases after chemotherapy[J]. Ann Surg Oncol, 2021,28(11):6805-6813. DOI: 10.1245/s10434-021-09824-z.
- [12] Tsili AC, Alexiou G, Naka C, et al. Imaging of colorectal cancer liver metastases using contrast-enhanced US, multidetector CT, MRI, and FDG PET/CT: a meta-analysis[J]. Acta Radiol, 2021,62(3):302-312. DOI: 10.1177/0284185120925481.
- [13] O'Connell E, Galvin R, McNamara DA, et al. The utility of preoperative radiological evaluation of early rectal neoplasia: a systematic review and meta-analysis[J]. Colorectal Dis, 2020,22(9):1076-1084. DOI: 10.1111/codi.15015.
- [14] Liu W, Zhang ZY, Yin SS, et al. Contrast-enhanced intraoperative ultrasound improved sensitivity and positive predictive value in colorectal liver metastasis: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2021,28(7):3763-3773. DOI: 10.1245/s10434-020-09365-x.
- [15] Mirshahvalad SA, Hinzpeter R, Kohan A, et al. Diagnostic performance of [¹⁸F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2022,49(12):4205-4217. DOI: 10.1007/s00259-022-05871-0.
- [16] Steele SR, Chang GJ, Hendren S, et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer[J]. Dis Colon Rectum, 2015,58(8):713-725. DOI: 10.1097/DCR.0000000000000410.
- [17] Blomqvist L, Holm T, Gäranson H, et al. MR imaging, CT and CEA scintigraphy in the diagnosis of local recurrence of rectal carcinoma[J]. Acta Radiol, 1996,37(5):779-784. DOI: 10.1177/02841851960373P270.
- [18] Pema PJ, Bennett WF, Bova JG, et al. CT vs MRI in diagnosis of recurrent rectosigmoid carcinoma[J]. J Comput Assist Tomogr, 1994, 18(2):256-261. DOI: 10.1097/00004728-199403000-00016.
- [19] Schaefer O, Langer M. Detection of recurrent rectal cancer with CT, MRI and PET/CT[J]. Eur Radiol, 2007,17(8):2044-2054. DOI: 10.1007/s00330-007-0613-2.

- [20] Colosio A, Fornès P, Soyer P, et al. Local colorectal cancer recurrence: pelvic MRI evaluation[J]. *Abdom Imaging*, 2013,38(1):72-81. DOI: 10.1007/s00261-012-9891-5.
- [21] Guillem JG, Minsky BD. Extended perineal resection of distal rectal cancers: surgical advance, increased utilization of neoadjuvant therapies, proper patient selection or all of the above?[J]. *J Clin Oncol*, 2008,26(21):3481-3482. DOI: 10.1200/JCO.2007.15.6646.
- [22] Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial[J]. *Eur J Surg Oncol*, 2010,36(5):470-476. DOI: 10.1016/j.ejso.2009.11.011.
- [23] Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment[J]. *Ann Oncol*, 2010,21 Suppl 5:v93-97. DOI: 10.1093/annonc/mdq222.
- [24] Kaur H, Choi H, You YN, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations[J]. *Radiographics*, 2012,32(2):389-409. DOI: 10.1148/rg.322115122.
- [25] Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience[J]. *J Clin Oncol*, 2011,29(28):3753-3760. DOI: 10.1200/JCO.2011.34.9068.
- [26] Battersby NJ, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study[J]. *Ann Surg*, 2016,263(4):751-760. DOI: 10.1097/SLA.0000000000001193.
- [27] Bamba Y, Itabashi M, Kameoka S. Preoperative evaluation of the depth of anal canal invasion in very low rectal cancer by magnetic resonance imaging and surgical indications for intersphincteric resection[J]. *Surg Today*, 2012,42(4):328-333. DOI: 10.1007/s00595-011-0007-6.
- [28] Shihab OC, How P, West N, et al. Can a novel MRI staging system for low rectal cancer aid surgical planning?[J]. *Dis Colon Rectum*, 2011,54(10):1260-1264. DOI: 10.1097/DCR.0b013e31822abd78.
- [29] Fernandes MC, Gollub MJ, Brown G. The importance of MRI for rectal cancer evaluation. *Surg Oncol*. 2022;43:101739. DOI: 10.1016/j.suronc.2022.101739.
- [30] Shaikat A, Kaltenbach T, Dominitz JA, et al. Endoscopic recognition and management strategies for malignant colorectal polyps: recommendations of the US Multi-Society Task Force on

- Colorectal Cancer[J]. *Gastroenterology*, 2020,159(5):1916-1934.e2. DOI: 10.1053/j.gastro.2020.08.050.
- [31] Choi JY, Jung SA, Shim KN, et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma[J]. *J Korean Med Sci*, 2015,30(4):398-406. DOI: 10.3346/jkms.2015.30.4.398.
- [32] Tanaka S, Kashida H, Saito Y, et al. Japan gastroenterological endoscopy society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection[J]. *Dig Endosc*, 2020,32(2):219-239. DOI: 10.1111/den.13545.
- [33] Matsuda T, Fukuzawa M, Uraoka T, et al. Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study[J]. *Cancer Sci*, 2011,102(9):1693-1697. DOI: 10.1111/j.1349-7006.2011.01997.x.
- [34] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. *Histopathology*, 2020,76(2):182-188. DOI:10.1111/his.13975.
- [35] Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J]. *J Natl Compr Canc Netw*, 2022,20(10):1139-1167. DOI:10.6004/jnccn.2022.0051.
- [36] Pimentel-Nunes P, Libânio D, Bastiaansen B, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022[J]. *Endoscopy*, 2022,54(6):591-622. DOI: 10.1055/a-1811-7025.
- [37] Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016[J]. *Mod Pathol*, 2017,30(9):1299-1311. DOI: 10.1038/modpathol.2017.46.
- [38] Gress DM, Edge SB, Greene FL, et al. Principles of cancer staging[J]. 2017. DOI:10.1007/978-3-319-40618-3_1.
- [39] Martelli V, Pastorino A, Sobrero AF. Prognostic and predictive molecular biomarkers in advanced colorectal cancer[J]. *Pharmacol Ther*, 2022,236:108239. DOI: 10.1016/j.pharmthera.2022.108239.
- [40] Wang J, Yi Y, Xiao Y, et al. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS[J]. *Mod Pathol*, 2019,32(7):1053-1064. DOI: 10.1038/s41379-019-0212-1.
- [41] Sabiston, David C. Sabiston textbook of surgery[M]. 20 ed. Amsterdam: Elsevier, 2016.

- [42] 顾晋. 结直肠癌外科手术的切缘[J]. 中华胃肠外科杂志, 2022, 25(1): 36-39. DOI: 10.3760/cma.j.cn441530-20220104-00008.
- [43] Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?[J]. Br J Surg, 1982, 69(10): 613-616. DOI: 10.1002/bjs.1800691019.
- [44] 关旭, 王锡山. 结直肠肿瘤经自然腔道取标本手术的器官功能保护优势[J]. 中华胃肠外科杂志, 2022, 25(6): 500-504. DOI: 10.3760/cma.j.cn441530-20220303-00078.
- [45] Yuan Z, Weng S, Ye C, et al. CSCO guidelines for colorectal cancer version 2022: Updates and discussions[J]. Chin J Cancer Res, 2022, 34(2): 67-70. DOI: 10.21147/j.issn.1000-9604.2022.02.01.
- [46] Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022, 386(25): 2363-2376. DOI: 10.1056/NEJMoa2201445.
- [47] Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(1): 38-48. DOI: 10.1016/S2468-1253(21)00348-4.
- [48] Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer[J]. N Engl J Med, 2018, 378(13): 1177-1188. DOI: 10.1056/NEJMoa1713709.
- [49] Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. JAMA, 2018, 319(24): 2486-2496. DOI: 10.1001/jama.2018.7855.
- [50] Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2018, 19(5): 660-671. DOI: 10.1016/S1470-2045(18)30140-2.
- [51] André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23): 2207-2218. DOI: 10.1056/NEJMoa2017699.
- [52] Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors[J]. J Hematol Oncol, 2021, 14(1): 95. DOI: 10.1186/s13045-021-01095-1.

- [53] Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials[J]. *Lancet Oncol*, 2020,21(4):531-540. DOI: 10.1016/S1470-2045(19)30856-3.
- [54] Chen G, Peng J, Xiao Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer[J]. *J Hematol Oncol*, 2021,14(1):80. DOI: 10.1186/s13045-021-01089-z.
- [55] Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer[J]. *N Engl J Med*, 2022,386(24):2261-2272. DOI: 10.1056/NEJMoa2200075.
- [56] Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial[J]. *Lancet Oncol*, 2022,23(1):115-124. DOI: 10.1016/S1470-2045(21)00605-7.
- [57] Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-Mutated colorectal cancer[J]. *N Engl J Med*, 2019,381(17):1632-1643. DOI: 10.1056/NEJMoa1908075.
- [58] Strickler JH, Yoshino T, Graham RP, et al. Diagnosis and treatment of ERBB2-Positive metastatic colorectal cancer: a review[J]. *JAMA Oncol*, 2022,8(5):760-769. DOI: 10.1001/jamaoncol.2021.8196.
- [59] Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12[J]. *J Clin Oncol*, 2019,37(34):3212-3222. DOI: 10.1200/JCO.19.00308.
- [60] Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy[J]. *J Clin Oncol*, 2022,40(23):2546-2556. DOI: 10.1200/JCO.22.00032.
- [61] Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)[J]. *J Clin Oncol*, 2022,40(15):1681-1692. DOI: 10.1200/JCO.21.01667.
- [62] Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a

- randomised, open-label, phase 3 trial[J]. *Lancet Oncol*, 2021,22(1):29-42. DOI: 10.1016/S1470-2045(20)30555-6.
- [63] Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial[J]. *Lancet Oncol*, 2021,22(5):702-715. DOI: 10.1016/S1470-2045(21)00079-6.
- [64] Bando H, Tsukada Y, Inamori K, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer[J]. *Clin Cancer Res*, 2022,28(6):1136-1146. DOI: 10.1158/1078-0432.CCR-21-3213.
- [65] Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. *Nat Med*, 2020,26(4):566-576. DOI: 10.1038/s41591-020-0805-8.
- [66] Lin Z, Cai M, Zhang P, et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J]. *J Immunother Cancer*, 2021,9(11)DOI: 10.1136/jitc-2021-003554.
- [67] Rahma OE, Yothers G, Hong TS, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial[J]. *JAMA Oncol*, 2021,7(8):1225-1230. DOI: 10.1001/jamaoncol.2021.1683.
- [68] Fernandez LM, S ão Juli ão GP, Figueiredo NL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study[J]. *Lancet Oncol*, 2021,22(1):43-50. DOI: 10.1016/S1470-2045(20)30557-X.
- [69] Fokas E, Appelt A, Glynne-Jones R, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer[J]. *Nat Rev Clin Oncol*, 2021,18(12):805-816. DOI: 10.1038/s41571-021-00538-5.
- [70] Peters FP, Teo M, Appelt AL, et al. Mesorectal radiotherapy for early stage rectal cancer: a novel target volume[J]. *Clin Transl Radiat Oncol*, 2020,21:104-111. DOI: 10.1016/j.ctro.2020.02.001.

- [71] Zhu J, Liu A, Sun X, et al. Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer[J]. *J Clin Oncol*, 2020,38(36):4231-4239. DOI: 10.1200/JCO.20.01932.
- [72] Garant A, Vasilevsky CA, Boutros M, et al. MORPHEUS Phase II-III study: a pre-planned interim safety analysis and preliminary results[J]. *Cancers (Basel)*, 2022,14(15)DOI: 10.3390/cancers14153665.
- [73] Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation[J]. *Int J Radiat Oncol Biol Phys*, 2010,77(1):60-65. DOI: 10.1016/j.ijrobp.2009.04.056.
- [74] Tao R, Tsai CJ, Jensen G, et al. Hyperfractionated accelerated reirradiation for rectal cancer: an analysis of outcomes and toxicity[J]. *Radiother Oncol*, 2017,122(1):146-151. DOI: 10.1016/j.radonc.2016.12.015.